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Evaluation of epigenetic modulation of cyclooxygenase-2
as a prognostic marker for hepatocellular carcinoma
A Ferna´ndez-Alvarez1,4, C Llorente-Izquierdo2,4, R Mayoral2,3, N Agra2, L Bosca´2,3, M Casado1,3 and P Martı´n-Sanz2,3
Cyclooxygenases (COX-1 and 2) catalyze the ﬁrst step in prostanoid biosynthesis. They are implicated in homeostatic processes with
an important role in inﬂammation and carcinogenesis. In the liver, COX-2 expression is restricted to proliferation or dedifferentiation
situations. The COX-2 promoter contains numerous CpG islands that, when hypermethylated, result in transcriptionally silencing
thus regulating the growth of carcinoma cells. In this work, we investigated whether a correlation exists between COX-2 expression
and methylation signatures at the 50region of the gene in hepatoma cell lines and human hepatocellular carcinoma (HCC). We
also examined the acetylation status of the COX-2 promoter and the effects of histone deacetylase (HDAC) inhibitors on COX-2
expression. Our results suggest a signiﬁcant association between reduced COX-2 expression and promoter hypermethylation of
COX-2 and histone deacetylation in some hepatoma cell lines and in HCC. Treatment with demethylating agents or HDAC inhibitors
restored the expression of COX-2. Moreover, in an HCC cohort, a statistically signiﬁcant inverse association was observed between
COX-2 mRNA levels and promoter methylation. In agreement with these data, a reduction of overall survival of the patients was
observed after decreased COX-2 expression by promoter hypermethylation and histone H3 hypoacetylation.
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INTRODUCTION
Cyclooxygenases (COX-1 and -2) are the key enzymes in prostanoid
biosynthesis. COX-1 is constitutively expressed in many tissues,
whereas COX-2 is induced by a variety of stimuli such as growth
factors, pro-inﬂammatory stimuli, hormones and other cellular
stresses.1 Adult hepatocytes fail to induce COX-2 expression
regardless of the pro-inﬂammatory factors used; however, Kupffer,
stellate, hepatoma mouse cells and fetal hepatocytes retain the
ability to express COX-2 upon stimulation with lipopolysaccharide
(LPS) and pro-inﬂammatory cytokines.2,3 In this regard, we and
others demonstrated that partial hepatectomy (PH) induced COX-2
in hepatocytes and contributed to the progression of cell cycle after
PH.4,5 In addition to liver regeneration after PH or hepatotoxic
agents, expression of COX-2 has been detected in animal models of
cirrhosis,6 in human hepatoma cell lines,7,8 in human hepatocellular
carcinoma (HCC)9 and after hepatitis B or C virus infection.10,11
Nevertheless, recent data reported that COX-2 mRNA levels were
signiﬁcantly higher in the adjacent liver than in HCC12 and there
was an inverse correlation between COX-2 expression and the
differentiation grade and poor prognosis of HCC.13 Therefore,
although the antiapoptotic feature of COX-2 generally supports
cancer cell growth, COX-2 downregulation in advanced HCC may be
advantageous and speciﬁc for HCC development. The mechanisms
regulating the expression of COX-2 at speciﬁc stages of HCC
development remain unknown.
COX-2 is widely regarded as a potential pharmacological target
for preventing and treating cancer disease mainly in colorectal
cancer. Thus far, therapeutic strategies have focused on selective
inhibitors of COX-2 activity; however, less attention has been paid
to identifying anticancer agents that suppress the expression of
COX-2. The 50-untranslated region of the COX-2 gene contains
binding sites for numerous regulatory transcription factors
including two nuclear factor-kB motifs, two activator protein 1
sites and two cAMP-response elements (CREs) among other.14
However, the regulation of the expression of COX-2 is much more
complex; it is known that COX-2 expression is also regulated by
genomic DNA and chromatin modiﬁcations and by post-
transcriptional regulation via its 30-untranslated region.15
DNA methylation and histone modiﬁcations represent the major
epigenetic mechanisms implicated in the regulation of gene
transcription in mammals. COX-2 promoter contains numerous
CpG islands that, when hypermethylated, result in transcriptional
silencing and this regulates the survival of carcinoma cells and
affects clinical outcomes in gastric cancer.16,17 The COX-2 promoter
activation by inﬂammatory mediators in human ﬁbroblasts and
mouse macrophages is mediated by the histone acetyltransferase
p300/CBP-associated factor.18 Diminished COX-2 expression in
ﬁbroblasts due to epigenetic abnormality in the form of histone
hypoacetylation has a key role in the pathogenesis of idiopathic
pulmonary ﬁbrosis.19 Recently, it has been reported that induction
of COX-2 by hepatitis B virus depends on the demethylation of the
COX-2 promoter by downregulating the DNA methyltransferase 3B
and the increased binding of transcription factors.20
In this work, we have monitored the epigenetic marks (that is,
DNA methylation and histone acetylation) at the COX-2 promoter
in hepatoma cells lines and HCC biopsies. The results shown in this
study suggest that the reduced COX-2 expression in some
hepatoma cell lines and HCC is closely associated with the
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methylation status and histone deacetylation. Treatment with
demethylating agents or histone deacetylase (HDAC) inhibitors
restored the expression of COX-2. In agreement with these data, a
reduction of overall survival (OS) of the patients was observed
after decreased COX-2 expression by promoter hypermethylation
and histone H3 hypoacetylation.
RESULTS
COX-2 expression and protein levels in HCC cell lines
COX-2 mRNA and protein levels were analyzed in six human cell
lines using human hepatocytes as control. WRL68, which is
derived from the human liver embryo, exhibited the highest COX-
2 mRNA expression whereas HepG2 and HuH-7 liver carcinomas
showed low levels of COX-2 mRNA and protein (Figures 1a and b).
Prostaglandin E2 levels, measured in cell supernatants, correlate
with COX-2 protein levels (Figure 1c).
Methylation analysis of COX-2 promoter in hepatic cell lines
It has been suggested that hypermethylation of certain CpG sites
on COX-2 promoter results in transcriptionally silencing and this
regulates the growth of carcinoma cells.17,21,22 The MethPrimer
analysis of the COX-2 genomic region organizes the CpG sites in
the 50region into three CpG islands (Figure 2a). The ﬁrst two
islands (A and B) are located in the promoter region and they do
not overlap with previously identiﬁed binding sites (C/EBP, nuclear
factor of activated T-cells or AP1).23 The third one (C) covers a
domain including the CRE-binding site with a main function in
transcriptional regulation, the ﬁrst exon, including both the coding
and noncoding regions, and the initial part of the ﬁrst intron.
We analyzed ﬁrst by methylation-sensitive restriction assay
(MSRA) the methylation state in several CpG sites to asses if there
was a correlation between methylation signatures and COX-2
expression in different hepatic cell lines as compared with the
human liver. HuH-7 and CHL cells, as well as the human liver,
presented a non-methylation pattern along the studied region.
Although different patterns were found in all the cell lines
analyzed, no correlation between CpG methylation and the COX-2
mRNA levels was observed, even considering separately each CpG
site (Figure 2b). We further quantiﬁed the methylation size by
sequencing 6, 8 and 20 CpGs on the CpG islands A, B and C,
respectively (Figure 2c). The pyrosequencing data are in accor-
dance with the MSRA results. The ﬁrst two CpG islands were
remarkably hypermethylated in Hep3B and HuH-6, while they
remained unmethylated in CHL and WRL68 cells. Moreover,
HepG2 and HuH-6 but not HuH-7 cells presented a hypermethyla-
tion pattern in CpG island C. In this region, Hep3B and CHL
presented a low methylation proﬁle. The analysis of a pool of
control human liver DNA showed that normal liver presents
unmethylated CpGs all along this region. The results obtained by
both assays indicate that it is not possible to predict the basal
expression of COX-2 from the methylation data. The WRL68 cell
line, which presents the highest levels of COX-2 expression,
showed the same methylation proﬁle than the human liver or
HuH-7 cells, both with negative expression levels.
We then analyzed by pyrosequencing the effect of the
demethylating agent 5-aza-20-deoxycytidine (AzadC) on COX-2
CpG islands. The percentage of COX-2 global CpG islands
methylation decreased from 80 to 59% in HuH-6, and from 43
to 33% in Hep3B cells after AzadC treatment (Figure 3a). No
decrease was observed in HuH-7 cells that presented a low
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)Figure 1. COX-2 expression and protein levels in HCC cell lines. Cells
were plated in 100-mm dishes and grown to 60–70% confluence in a
culture medium supplemented with 10% fetal bovine serum.
(a) Total RNA was prepared from hepatic cell lines and COX-2
mRNA was analyzed by quantitative PCR. COX-2 mRNA amounts
were calculated as relative quantitation (RQ) and normalized to the
expression of 18S levels. Values represent fold change relative to
human hepatocytes (HH). (b) Total cellular extracts were prepared
from hepatic cells and protein (50mg per lane) was analyzed by
western blot. A representative western blot out of four is shown. The
expression of target protein was normalized to that of GAPDH.
Densitometric analysis of COX-2 expression using HH as reference
control (100%) is also shown (c) Prostaglandin E2 (PGE2) concentra-
tion was determined by enzyme immunoassay in the supernatant of
the cells. Data are reported as means±s.d. of four independent
experiments. *Po0.05 and **Po0.01 vs HH.
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methylation percentage in basal conditions. In the same condi-
tions, COX-2 mRNA levels were analyzed by reverse transcription-
quantitative PCR. HuH-6 and Hep3B presented a 5- and 78-fold
induction of COX-2 expression, respectively. Furthermore, HuH-7
cells presented a fourfold induction of COX-2 expression after
treatment with AzadC despite the absence of changes in the
methylation pattern (Figure 3b), highlighting the relevance of
promoter demethylation in the regulation of COX-2, although
other alternative mechanisms may coexist. To asses if this
differential response is a speciﬁc mechanism related to COX-2
regulation, we determined the amount of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA normalized to the
expression of 18S in all cell lines used. AzadC produced a minor
reduce in GAPDH expression, with an effect that was quantita-
tively comparable in the three cell lines analyzed.
Role of histone acetylation on COX-2 transcription in HCC cells
To evaluate the effect of histone modiﬁcations on COX-2
expression, we ﬁrst examined the effects of two HDAC inhibitors
(HDACis), sodium butyrate (NaB) and suberoylanilide hydroxamic
acid (SAHA), on COX-2 mRNA and protein levels in hepatic cell
lines. Treatment of cells with the inhibitors promoted a marked
increase of COX-2 mRNA levels at 16 h (no changes were found at
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Figure 2. Methylation analysis of CpG islands at COX-2 gene in HCC cells. (a) Representative scheme of putative CpG islands (A, B, C) identified
by bioinformatic analysis and CpG dinucleotides detected by MSRA (black arrows) in the 50 upstream region of COX-2 gene. The non-coding
(gray rectangle) and coding (black rectangle) regions of the first exon are also shown. (b) The MSRA technique was used to analyze the
methylation profile of CpG sites in the COX-2 promoter region using DNA from the human liver and six liver derived cell lines. DNA digested
with MspI (M), HpaII (H) or no restriction enzyme (N) was amplified by PCR using primers recognizing the  431,  372,  138 or 75/84/98 CpG
sites. A representative ethidium bromide-stained agarose gel is shown for each PCR reaction. A scheme of methylation state is represented
using white balls (non-methylated) or black balls (methylated). The COX2 expression levels in the cell lines are represented with a black
triangle. (c) Profiles of the percentage of methylation in the each CpG (A, B, C) islands of COX-2 promoter in the human liver and hepatic cell
lines analyzed by bisulfite pyrosequencing. The global promoter methylation percentage for each sample is shown in the right panel.
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6 h) except for WRL68 (Supplementary Figure S1). A signiﬁcant
increase in COX-2 was observed in Hep3B, HuH-6 and HuH-7
hepatoma cells by the effect of both NaB and SAHA after 24 h of
treatment (Figure 4a). Prostaglandin E2 levels well correlated with
COX-2 protein (Figure 4b). No changes were detected in HDAC1, 2,
3 and SIRT1 protein levels by the effect of HDACis in HCC cells. The
acetylation status of histone H3 and histone H4 was evaluated
(Figure 4a) and a signiﬁcant increase in acetylated histones H3 and
H4 was observed in HCC cells. Moreover, when global HDAC
activity was measured by using a colorimetric detection assay, the
highest activity corresponded to Hep3B and HuH-6 cells. As
expected, global HDAC activity was inhibited by treatment of the
cells with NaB and SAHA (Figure 4c). These results suggest that
histone acetylation regulates COX-2 expression in some HCC cells.
We determined whether there was a direct link between the
increased H3 and H4 acetylation and COX-2 expression, analyzing
the effects of NaB on acetylated histones recruitment at the COX-2
promoter. We ascertained the interaction of Ac-H3 and Ac-H4 all
along the 50 region of the COX-2 human gene using a standard
chromatin immunoprecipitation assay followed by real-time PCR.
The a-RNA polymerase antibody was used as a control of gene
activity. Four different primer pairs were used to cover the
complete regulatory sequence starting on a distal promoter
region, and ending on the ﬁrst intronic region. We found an
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increased Ac-H3 association both in HuH-6 and HuH-7 cells, with
a higher signal in HuH-6 cells after treatment with NaB. The
increased association is higher in the proximal promoter and the
noncoding part of the ﬁrst exon, which includes the CRE
regulatory site. An increased Ac-H4 association was only seen on
HuH-6 cells chromatin (Figure 5a).
To investigate whether histone acetylation is associated with
HCC, we determined the COX-2, histone H3 and aceylated-H3
immunoreactivity in tumor tissue samples. Ac-H3 staining was
observed primarily in the cell nuclei (Figure 5b). Immunoreactivity
of Ac-H3 protein ranged from 138% to 34% vs a positive control
tissue (amygdala) considered as 100%.24 In the study cohort, high
expression of Ac-H3/H3 ratio was detected in 67% of HCCs.
Assessment of survival in these patients revealed that high Ac-H3/
H3 ratio was correlated with a favorable disease-speciﬁc survival
(P¼ 0.021; Figure 5c). Moreover, an increased COX-2 immunor-
eactivity was observed in the tumors with a major Ac-H3/H3 ratio
(Figure 5b).
It has been described that demethylating agents and HDACis
function in synergy by depleting methyltransferase activity and
reversing the formation of transcriptionally repressive chromatin
structure.25,26 Combined treatment with AzadC and NaB or SAHA
induced a higher increase of functional COX-2 protein levels than
the HDACis alone. Moreover, both drugs decreased DNMT1
protein levels in HCC cells (Supplementary Figure S2).
Methylation analysis of COX-2 promoter in primary HCCs
Quantitative real-time RT–PCR analysis of HCC samples revealed
signiﬁcantly higher COX-2 mRNA levels vs normal human liver.
Moreover, 86% patients showed a higher COX-2 expression in the
non-tumoral biopsies compared with their paired tumoral sections
(Figure 6b), as it has been described previously.12 To determine
whether aberrant methylation of COX-2 is associated with HCCs,
we performed bisulﬁte sequencing of CpG islands A, B and C at
COX-2 locus from 23 tumor and non-tumor clinical samples of HCC
patients. Consistent with the expression levels, the COX-2
promoter was methylated extensively in tumor tissues compared
with the corresponding nontumor sections (Figure 6c). However,
the hypermethylation of COX-2 promoter was exclusively found in
57% of the tumor tissues with respect to their non-tumor
counterparts (Figure 6a). The average global methylation in these
samples was 31% and 7.6% of tumor and non-tumor tissues,
respectively. In all cases, the altered methylation pattern was
clearly seen in the CpG islands B and C but not in the A. Next, we
investigated whether this differential methylation status was
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correlated with COX-2 expression in clinical samples of HCC. A
statistically signiﬁcant inverse association was observed between
the COX-2 mRNA levels and methylation status in HCC (Figure 6d).
Moreover, OS was signiﬁcantly different according to the
methylation status without signiﬁcant differences in disease-free
survival rates (Figure 6e). A hypermethylation of COX-2 promoter
was signiﬁcantly associated with a poor OS (P¼ 0.04). We did not
observe any signiﬁcant association with other clinical signs
(Table 1).
DISCUSSION
Increased COX-2 expression has been found in the early stages,
but is lost in advanced HCC.13 Moreover, COX-2 mRNA levels were
signiﬁcantly higher in the adjacent healthy liver than in HCC and
lower in HCC than in nonalcoholic steatohepatitis disease.27
Therefore, many questions remain unsolved regarding the
contribution of COX-2 to induce/regulate tumorigenesis. As the
mechanisms regulating COX-2 expression at speciﬁc stages of
HCC progression remain unknown, we hypothesize that COX-2
expression could be regulated by epigenetic changes such as DNA
methylation and histone acetylation. Here, we show that the low
COX-2 expression in some HCC lines and in HCC biopsies is
associated with COX-2 promoter hypermethylation and histone
deacetylation. Conversely, treatment with HDACis or
demethylating agents increased the expression of COX-2.
DNA methylation is a predominant mechanism used to
inactivate relevant genes during HCC tumorigenesis. Recent
ﬁndings support the hypothesis that hypomethylation of the
DNA surrounding the proximal promoter region is a prerequisite
for activation of oncogenes, whereas hypermethylation leads to
gene silencing of putative tumor-suppressor genes.28 The
therapeutic and chemopreventive signiﬁcance of methylation
patterns in human HCC have been reported; Lee et al.29 showed
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that the APC, GSTP1 RASSF1A, p16, COX-2 and E-cadherin genes
were frequently methylated in HCC. Moreover, COX-2, p16,
RASSF1A and TIMP-3 were not methylated in liver cirrhosis and
chronic hepatitis from patients without concurrent HCC. To date,
frequent and aberrant methylation of Ras and Janus kinase/signal
transducer and activator of transcription inhibitors in HCC resulted
in persistent activation of the Ras and Janus kinase/signal
transducer and activator of transcription pathways.30 The same
group31 has investigated the global levels of DNA methylation as
well as the methylation status of 105 putative tumor-suppressor
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higher percentage of COX-2 promoter methylation in the tumoral tissue (n¼ 13). (e) OS and disease-free survival (DFS) curves according
to COX-2 methylation status using Kaplan–Meier survival plots. OS is significantly associated with the methylation status of COX-2 (P¼ 0.04).
Gray line, patients with a hypermethylation status in the tumoral tissue; black line, patients without alteration in percentage of methylation of
COX-2 promoter between tumor and their non-tumor counterparts.
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genes and found that the extent of genome-wide hypomethyla-
tion and CpG hypermethylation correlates with biological features
and clinical outcomes of HCC patients. Furthermore, methylation
also appears to be an early event, suggesting that this may
precede cirrhosis. The more aggressive subclass A of HCC
displayed a very high frequency of gene promoter hypermethyl-
ation, a condition similar to the CpG island methylator phenotype
described in human colorectal cancer.32 Recently, Yang et al.33
have identiﬁed genes whose methylation and mRNA levels are
associated with recurrence after resection for HCC using
integrated analysis by whole-genome DNA methylation and
mRNA expression data. They suggest that potential novel
oncogenes (PSRC1, MYO1E), tumor-suppressor genes (CFH,
MYRIP) and TGF, Wnt and cytoskeletal remodeling were the
major pathways enriched with the recurrence predicting genes.
Regarding COX-2, it has been reported that epigenetic silencing of
COX-2 affects clinical outcome in gastric cancer.16
To clarify the methylation status of the COX-2 promoter in HCC
three CpG islands, identiﬁed through bioinformatic analysis, were
examined by pyrosequencing in six hepatic cell lines exhibiting
different COX-2 expression levels. Furthermore, CpG sites located
at  431,  372,  138 and þ 75/84/98 were analyzed by the
MSRA analysis. We observed a broad range of methylation from
2% in WRL68 to 43% in Hep3B cell line, without a correlation
between these percentages and COX-2 expression. Nevertheless,
we could demonstrate that treatment with a demethylating agent,
AzadC, readily induced COX-2 expression in HCC cells. These
results suggest that the methylation status of the promoter can
regulate COX-2. However, we could not discard indirect mechan-
isms regulating COX-2 expression, as observed in HuH-7 cells, in
which the treatment with demethylating agent increased the
COX-2 mRNA levels despite the permanent hypomethylation
status of the promoter in this cell line. In fact, it has been
suggested that in colorectal cancer cells, AzadC is capable of
inﬂuencing other factors involved in gene expression such as
proteins with a methyl-binding domain or histone modiﬁcations.34
Prostaglandin E2 promotes intestinal tumor growth via DNA
methylation of certain tumor-suppressor and DNA-repair genes by
enhancing their promoter methylation.35 Moreover, hyper-
methylation of COX-2 gene promoter has been identiﬁed as an
independent prognostic factor in gastric cancer patients.16 These
results prompted us to study whether the methylation of COX-2
promoter was related with the COX-2 expression in HCC. In
agreement with previous work,9,36 COX-2 mRNA levels were
higher in the adjacent liver tissue than in HCC in the 86% of the
studied biopsies. When we analyzed the methylation proﬁle at
three CpG islands, we could classify the samples in two groups:
43% of samples exhibited a low percentage of COX-2 promoter
methylation without differences between the tumoral and non-
tumoral tissue, whereas the remaining 57% showed a higher
percentage of COX-2 promoter methylation in the tumoral tissue.
This methylation status was associated with COX-2 expression as
suggested by the signiﬁcant differences in the levels of COX-2
between both groups. These results suggest that the promoter
hypermethylation is an important regulatory mechanism of COX-2
expression in HCC.
The long-term survival of patients with HCC is unsatisfactory,
in part because of the high rate of recurrence after curative
surgical resection of hepatocellular carcinoma. There have been
many reports on the prognostic signiﬁcance of epigenetic
alterations at the promoter region of genes associated with
HCC. For example, patients with E-cadherin or GSTP1 methylation
showed poorer survival than those without.29 In this study, COX-2
methylation was associated with poor prognosis in HCC. Although
it remains unclear how COX-2 methylation affects prognosis in
these cases, methylation of COX-2 may occur concordant with
other methylation alterations and could be part of the genome-
wide methylation defect in these cancers.37 Thus, COX-2 may
integrate a CpG island methylator phenotype associated with poor
prognosis.
NaB, a short-chain fatty acid that is normally present in the
human colon as a product of the metabolic degradation of
complex carbohydrates, was the ﬁrst compound found to possess
histone deacetyltransferase-inhibiting activity.38 Different pre-
clinical studies with NaB showed its ability to inhibit HCC cell
growth. Beside NaB, hydroxamic acids including trichostatin A and
SAHA are undergoing phase I and II clinical trials to validate their
potential use as anticancer drugs for solid and hematological
tumor treatment either as monotherapies or in combination with
other cytotoxic agents. Our data demonstrate that treatment of
HCC cells with NaB or SAHA increased COX-2 expression and
restored acetylation of histones H3 and H4 around COX-2
promoter in some hepatoma cell lines. An interesting ﬁnding in
our study was that HCC patients with a major percentage of
histone H3 acetylation had a better survival. Thus, it is speculated
that epigenetic mechanism that implies a less expression of COX-2
are linked to poor prognosis of patients with hepatocarcinoma.
There are some different results concerning the effect of
HDACis on COX-2 expression. To date, butyrate and trichostatin A
suppress COX-2 expression in HT-29 cells by inhibition of RNA
polymerase II elongation on the COX-2 gene and the same occurs
for c-myc.39 In KYSE450 (esophageal squamous cell carcinoma)
and in 184B5/HER (Neu-transformed breast cells), HDACis suppress
PMA-mediated induction of COX-240 and in human non-small cell
lung cancer cells, trichostatin A-induced apoptosis and decreased
the levels of COX-2 mRNA and protein expression.41 However,
NaB and trichostatin A accentuated LPS-induced COX-2 gene
expression through mitogen-activated protein kinase-dependent
increase of phosphorylation and acetylation of histone H3 at the
COX-2 promoter and by decreasing C/EBPd levels.42,43 These
Table 1. Clinicopathological features of 23 HCC patients
Methylation status of tumor biopsies P
Unmethylated Methylated
Sex 0.339
Male 9 9
Female 1 4
Age 70.2±7.2 63.46±15.6 0.284
Etiology 0.709
HBV 1 1
HCV 4 4
Ethanol 1 3
HCT 1 0
NA 3 5
Cirrhosis 0.673
Positive 3 5
Negative 7 8
Tumor size 0.372
45 2 6
o5 6 6
NA 2 1
Histological grade 0.282
WD 5 9
MD 3 3
UD 0 1
NA 2 0
Abbreviations: HBV, hepatitis B infection; HCC, human hepatocellular
carcinoma; HCT, Hemochromatosis; HCV, hepatitis C infection; MD;
moderate differentiated; NA, not assigned; UD, undifferentiated; WD, well
differentiated.
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results and our data suggest that the effect of HDACis on COX-2
activation does not appear to be common to all the cell types and
even not related with their anti-tumoral activity.
In conclusion, COX-2 expression appears to be regulated at ﬁrst
instance by promoter methylation and histone acetylation in
hepatoma cell lines and HCC. Our results indicate that alterations
in promoter methylation of COX-2 occur exclusively in hepatic
tumor regions of HCC and that aberrant methylation of COX-2 in
HCC leads to poor prognosis after surgical resection. Primary
tumor COX-2 methylation status may therefore be used as a
signature to decide a more aggressive treatment in HCC. Our data
suggest that epigenetic mechanisms that imply reduced COX-2
expression are linked to poor prognosis of HCC patients. The
identiﬁcation of the crosstalk between epigenetic signatures and
transcription factors activity appears to be relevant for the
implementation of new HCC therapeutic approaches.
MATERIALS AND METHODS
Cell lines and tissue samples
A total of 23 individual tumoral and paired non-tumoral frozen HCC tumors
were obtained from the de Spanish Tumor Bank Network of the Centro
Nacional de Investigaciones Oncolo´gicas. Institutional Review Board
approval was obtained for these studies and all participants provided
written informed consent. All tissues were evaluated by pathologists by
means of hematoxylin/eosin staining. Histological graded as well (WD),
moderate (MD) or undifferentiated (UD) was determined according to the
Edmondson and Steiner classiﬁcation, following World Health Organization
recommendations. Clinicopathological parameters of HCC patients are
summarized in Table 1. This retrospective cohort study used a prospective
database during 8-year period (partial liver resection from 2001 to 2009,
follow-up data until 2011). Death from any cause was used to determine
the OS rate. Disease-free survival was deﬁned as a patient who was alive at
the end of the follow-up period. All specimens examined in this study were
collected at primary surgery. At the time of the last follow-up 5 (21.7%)
patients were alive and 18 (78.3%) patients had died of disease (median OS
44.2 months, conﬁdence interval 95%¼ 27–61%).
The human liver cell lines WRL68, Chang liver (CHL) and the hepatoma
cell lines HepG2 and Hep3B were purchased from the American Type
Culture Collection (ATCC, Manassas, VA, USA). All these cells lines were
authenticated by ATCC and were expanded twice, and stored in liquid N2.
Expansions from these clones were used up to 6 months in culture. HuH-6
and HuH-7 cell lines were kindly provided by Dr Perret (Institut Cochin,
CNRS UMR8104, University Paris-Descartes, Paris, France) and Dr Kern
(Department of General Pathology, University Hospital Heidelberg,
Heidelberg, Germany), respectively. Cells were grown on Eagle’s Minimal
Essential Medium or Dulbecco’s modiﬁed Eagle’s medium (Sigma Chemical
Co. St Louis, MO, USA) supplemented with 10% fetal bovine serum and
antibiotics (50mg each of penicillin, streptomycin and gentamicin per ml).
The cells were treated with the following drugs alone or in combination:
2.5mM NaB (Sigma), 2.5mM SAHA (Sigma) and 5 mM 5-aza-20-deoxycytidine
(AzadC; Sigma). Timing and concentration curves were performed
previously to determine the optimal concentrations.
RNA extraction and quantitative real-time PCR analysis
Total RNA from single-freeze cryopreserved pooled human hepatocytes
(HPCH10 CryostaX, XenoTech, Lenexa, KS, USA), cell lines and liver biopsy
samples was extracted by using TRIzol reagent (Life Technologies, NY,
USA). RNA (1mg) was reverse transcribed using a Transcriptor First Strand
cDNA Synthesis Kit following the manufacturer’s indications (Roche
Applied Science, Indianapolis, IN, USA). The cDNA was used as template
for real-time PCR through Taqman probes. COX-2 (Hs00153133_m1),
GAPDH (Hs99999905_m1) or 18S (Hs99999901_m1) assay on demand
gene expression products were used (Life Technologies). Real-time PCR
was performed using a MyiQ detection system (Bio-Rad Laboratories,
Hemel Hempstead, UK) and thermocycling parameters were 95 1C for
10min, 50 cycles of 95C for 15 s followed for 60 1C for 1min. Each sample
was run in triplicate and was normalized to 18S levels. Three replicates
were then averaged, and fold induction was determined in a DDCt based
fold-change calculations.
Western blot analysis
Extracts from cells (2–3 106) or cryopreserved pooled human hepato-
cytes were obtained as described previously.44 The relative amounts of
each protein were determined with the following polyclonal or
monoclonal antibodies: COX-2 (sc-1747, Santa Cruz Biotechnology, Santa
Cruz, CA, USA); HDAC 1, 2, 3 (Santa Cruz and Cell Signaling, Boston, MA,
USA); sirtuin 1 (SIRT1; Millipore, Billerica, MA, USA); anti-histone 3 (H3), anti-
histone 4 (H4) and anti-acetylated H4 (Ac-H4; Abcam, Cambridge, UK); anti-
acetylated H3 (Ac-H3; Millipore) and DNA (cytosine-5) methyltransferase 1
(DNMT1; Imgenex, San Diego, CA, USA). After incubation with the
corresponding anti-rabbit or anti-mouse horseradish peroxidase-
conjugated secondary antibody, blots were developed by the ECL
protocol (GE Healthcare, Chalfont St Giles, UK). Target protein band
densities were normalized with the expression of GAPDH (Life
Technologies). The blots were revealed, and different exposition times
were performed for each blot with a charged coupling device camera in a
luminescent image analyzer (Chemi-Doc XRS, Bio-Rad) to ensure the
linearity of the band intensities. Densitometric analysis was expressed in
arbitrary units.
Immunohistochemical staining
Two- to four-micrometer thick parafﬁn-embedded tissue microarrays and
complete sections were cut onto Dako slices (Dako, Glostrup, Denmark) by
Immunohistochemistry unit of the Centro Nacional de Investigaciones
Oncolo´gicas, and subsequently dewaxed, rehydrated and subjected to
antigen retrieval by heating in PTLink with 50mM Tris/EDTA pH 9.0. The
slides were cooled and treated with peroxidase-blocking solution (Dako)
for 5min. Sections were immunostained with a COX-2 antibody
(NeoMarkers, Suffolk, UK), anti-histone H3 (Abcam) and acetyl-histone H3
(K9; Abcam) in a Autostainer Plus (Dako). In parallel, each tissue section was
also incubated with a rabbit anti-mouse antiserum and was used as a
negative control. Microphotographs were taken with an EnVision FLEX
system (Dako). The images were processed with the Image J software
developed at the National INstitutes of Health (Bethesda, MD, USA).
Integrated density was calculated for each image after background
substraction. The background corresponds to the immunoreactivity in the
negative control tissue (normal liver). The percentage of the ratio between
acetyl histone H3 and histone H3 immunoreactivity was calculated
considering 100% the ratio of a positive control tissue (amygdala) added
to tissue microarray slides.24
Determination of metabolites and enzymatic activities
Prostaglandin E2 was determined in culture media by speciﬁc immunoas-
say (Arbor Assays, Ann Arbor, MI, USA).44 HDAC total activity was analyzed
in cell extracts by a ﬂuorimetric detection method (HDAC Assay Kit,
Upstate, Billerica, MA, USA).
Genomic DNA isolation, bisulﬁte treatment and methylation-
speciﬁc analysis
Genomic DNAs were isolated from cells or resected specimens using the
Maxwell 16 DNA puriﬁcation Kit (Promega, Madison, WI, USA) and DNA
samples were treated with bisulﬁte using the EZ DNA Methylation-Gold Kit
(Zymo Research, Irvine, CA, USA) to convert cytosine to uracil, according to
the manufacturer’s instructions. A two steps nested-PCR strategy was used
to amplify COX-2 CpG islands starting with 1 ml of bisulfate-treated DNA in
a ﬁnal volume of 25ml. In the ﬁrst step, a 412-bp fragment was ampliﬁed
for CpG islands A and B, and a 476-bp fragment for the CpG island C. The
PCR cycle used was as follows: 95 1C for 10min, 40 cycles at 95 1C for 30 s,
58 1C (islands A and B) or 56 1C (island C) for 30 s and 72 1C for 45 s and a
ﬁnal extension at 72 1C for 10min. A 2.6ml volume of the ﬁrst PCR product
was used as a template for a new round of ampliﬁcation in a ﬁnal volume
of 65 ml using a pair of internal primers, one of them a biotin-50-modiﬁed
oligonucleotide. A fragment of 368 bp for CpG islands A and B or a 290-bp
fragment for CpG island C was ampliﬁed using the PCR cycle described
above. The ﬁnal product was puriﬁed and pyrosequenced for methylation
analysis by the DNA Analysis Facility of the Instituto de Biomedicina de
Valencia, Spain. All used primers are detailed in the Supplementary Table 1.
The methylation status was also evaluated by MSRA. After isolation
genomic DNA samples were treated with restriction enzymes MspI and
HpaII and ampliﬁed by PCR as follows: 95 1C for 10min and then 30 cycles
at 95 1C for 15 s, 58 1C for 30 s and 72 1C for 30 s and a ﬁnal extension at
72 1C for 7min. A non-digested sample was used as the positive control.
PCR products were visualized on a 2% agarose gels stained with ethidium
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bromide. Speciﬁc primers used for ampliﬁcation of each CpG site are
shown in the Supplementary Table 2.
Chromatin immunoprecipitation analysis
Evaluation of histone acetylation levels was performed by chromatin
immunoprecipitation analysis as described previously,45 using isolated
nuclei from formaldehyde-cross-linked HuH-6 and HuH-7 cells. Chromatin
obtained from untreated (control) or 16 h NaB-treated cells was
immunoprecipitated using antibodies against: RNA polymerase II (sc-899,
Santa Cruz), Ac-H3 (K9, K14) (06-599, Millipore) and Ac-H4 (K12) (07-595,
Millipore). The amount of DNA in each chromatin immunoprecipitated was
quantiﬁed by real time–PCR on a 7500 Fast System (Life Technologies)
using the SYBR Green PCR reagent. The oligonucleotides used for each PCR
reaction are listed in the Supplementary Table 3.
Data analysis
Data are expressed as mean±s.d. (n ranged from three to ﬁve
independent experiments). The Mann–Whitney U test was used for ordinal
variables. Survival length was determined from the day of primary tumor
surgery to the date of death or last clinical follow-up. The Kaplan–Meier
method was used for survival analysis grouping with COX-2 methylation or
acetylation status. Differences between curves were analyzed using the
log-rank test. The statistical software SPSS Statistics 20 (IBM, Armonk, NY,
USA) was used; a P-value of o0.05 was considered signiﬁcant.
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